Novel Compounds Targeting TLR/mTOR Signaling Pathways for Multiple Sclerosis Treatment

Overview

This research program investigates novel compounds that target toll-like receptors (TLR) and the mTOR signaling pathway as a therapeutic approach for Multiple Sclerosis (MS). The central hypothesis is that TLR inhibition and reversal of mTOR signaling can reduce neuroinflammation and neurodegeneration by reversing cell death and increasing developmental myelination. The work builds on prior validated success using Zinc Ortho-methyl Carbonodithioate in neurodegenerative disease models, including epilepsy (via Nrf2/p-AKT pathways) and Alzheimer's disease (via SIRT1/p-JNK pathways). The research team has demonstrated ability to assess compounds through behavioral analyses, protein expression studies, and molecular docking methods.

Technical specifications

Research approach and capabilities:

• Biological screening through computational studies to identify promising compounds for MS treatment
• Experimental validation using MS mouse models for in vivo testing
• Behavioral assessments including Morris Water Maze and Y-maze tests
• Analysis of TLR/mTOR signaling pathways for target identification
• Evaluation of neuroinflammatory marker expression
• Histological and morphological brain tissue analysis
• AAV injection techniques to study brain changes
• Molecular docking methods for compound-protein interaction studies
• Protein expression analysis covering inflammatory, pre- and post-synaptic, survival, and apoptotic markers

Prior validated expertise:

• Reversal of PTZ-induced neuronal synapse deficits
• Improvement of oxidative stress-related memory impairment
• Inhibition of the amyloidogenic pathway in mouse brain models
• Upregulation of Nrf2/p-AKT pathways in epileptic models
• Regulation of SIRT1/p-JNK pathways in Alzheimer's models

Technology readiness level

This research is at an early-to-mid stage of preclinical development. The team has established proof-of-concept in related neurodegenerative conditions (epilepsy and Alzheimer's disease) using novel zinc-based compounds with demonstrated mechanistic validation. The Multiple Sclerosis application represents a new therapeutic direction requiring initial computational screening, compound selection, MS mouse model development, and comprehensive in vivo validation. Future work will progress through biological screening, experimental compound testing, behavioral analysis, signaling pathway analysis, and histological evaluation to establish therapeutic potential before advancing toward clinical translation.